|
Real-time Estimate
Tradegate
23:59:00 02/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 3.289 EUR | -74.70% |
|
0.00% | - |
| 02:10pm | Evotec, Plectonic Launch Research Collaboration on New T-Cell Approaches for Solid Tumors | MT |
| 11:15am | Evotec, Plectonic Biotech Partner on Research of Novel Immunotherapy for Solid Tumors | MT |
Company Valuation: Evotec
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 7,444 | 2,696 | 3,765 | 1,453 | 966.4 | 588 | - | - |
| Change | - | -63.78% | 39.63% | -61.41% | -33.49% | -39.16% | - | - |
| Enterprise Value (EV) 1 | 7,099 | 2,485 | 3,787 | 1,669 | 938.7 | 730.8 | 750.2 | 761.2 |
| Change | - | -65% | 52.43% | -55.93% | -43.75% | -22.15% | 2.64% | 1.47% |
| P/E | 32.7x | -15.4x | -45.3x | -7.38x | -9.4x | -2.82x | -7.68x | -174x |
| PBR | 5.44x | 2.27x | 3.37x | 6.89x | 1.19x | 0.92x | 1.11x | 1.13x |
| PEG | - | 0x | 0.9x | -0x | 0.2x | -0x | 0.1x | 1.8x |
| Capitalization / Revenue | 12x | 3.59x | 4.82x | 1.82x | 1.23x | 0.98x | 0.82x | 0.75x |
| EV / Revenue | 11.5x | 3.31x | 4.85x | 2.09x | 1.19x | 1.22x | 1.04x | 0.97x |
| EV / EBITDA | 66.2x | 24.4x | 57.1x | 74x | 22.8x | -10.7x | 15.9x | 8.04x |
| EV / EBIT | 173x | 119x | -142x | -11.7x | -16.7x | -2.83x | -18.5x | 29.3x |
| EV / FCF | 2,155x | 114x | -21.4x | -16.8x | -11.5x | -4.29x | -13.2x | 102x |
| FCF Yield | 0.05% | 0.88% | -4.67% | -5.95% | -8.71% | -23.3% | -7.59% | 0.98% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 1.3 | -0.99 | -0.47 | -1.11 | -0.58 | -1.174 | -0.4303 | -0.019 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 618 | 751.4 | 781.4 | 797 | 788.4 | 599.7 | 719.2 | 784.8 |
| EBITDA 1 | 107.3 | 101.7 | 66.35 | 22.56 | 41.1 | -68.1 | 47.3 | 94.62 |
| EBIT 1 | 41 | 20.85 | -26.63 | -142.5 | -56.2 | -258.5 | -40.66 | 25.99 |
| Net income 1 | 215.5 | -175.7 | -83.91 | -196.1 | -103.5 | -235.8 | -60.37 | 14.39 |
| Net Debt 1 | -345.3 | -211.8 | 22.09 | 216 | -27.66 | 142.8 | 162.2 | 173.2 |
| Reference price 2 | 42.500 | 15.260 | 21.280 | 8.195 | 5.450 | 3.306 | 3.306 | 3.306 |
| Nbr of stocks (in thousands) | 175,162 | 176,703 | 176,936 | 177,303 | 177,323 | 177,749 | - | - |
| Announcement Date | 12/04/22 | 12/05/23 | 24/04/24 | 17/04/25 | 08/04/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 33.93x | 6.05x | 18x | 0.95% | 49.74B | |
| -21.45x | 254.03x | -23.17x | -.--% | 44.98B | |
| 33.27x | 3.24x | 13.96x | -.--% | 42.52B | |
| 46.98x | 5.43x | 29.72x | -.--% | 40.78B | |
| 28.55x | 8.63x | 21.82x | 0.4% | 32.89B | |
| 33.17x | 5.43x | 24.66x | -.--% | 16.28B | |
| 23.86x | 2.08x | 9x | 1.13% | 14.4B | |
| 75.53x | 3.99x | 15.46x | -.--% | 13.48B | |
| Average | 31.73x | 36.11x | 13.68x | 0.31% | 31.88B | |
| Weighted average by Cap. | 27.03x | 49.18x | 12.22x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- EVT Stock
- EVT Stock
- Valuation Evotec
Select your edition
All financial news and data tailored to specific country editions
